Overall, we report a drug and signaling pathway with therapeutic potential, including proteins associated with cognitive deficits in normal mice or gene mutations that cause AD.Īs an irreversible neurodegenerative disease that causes cognitive deficits, Alzheimer's disease (AD) accounts for 60–80% of all types of dementia ( 1). Thus, key metabolites represent early indicators of the development of AD.

Multivariate statistical analysis showed that 14 metabolites were significantly upregulated, and 8 metabolites were downregulated in the model animals compared to the normal controls. A serum metabolomics assay was performed using UHPLC-LTQ Orbitrap mass spectrometry to delineate the metabolic changes and potential early biomarkers in APP/PS1 transgenic mice. The data also indicated that OMO are an efficacious prebiotic in an animal model of AD, regulating the composition and metabolism of the gut microbiota. 16S rRNA sequencing analyses indicated that OMO maintained the diversity and stability of the microbial community. Histological changes indicated that OMO ameliorated brain tissue swelling and neuronal apoptosis and downregulated the expression of the intracellular AD marker Aβ 1−42.

Behavioral experiments demonstrated that OMO significantly ameliorated the memory of the AD animal model. OMO were administered to APP/PS1 transgenic mice, and potential clinical biomarkers of AD were identified with metabolomics and bioinformatics. Therefore, this study was conducted to investigate whether OMO are clinically effective in alleviating AD by improving gut microbiota. Preliminary research has shown that oligosaccharides from Morinda officinalis (OMO) are a useful prebiotic and cause substantial memory improvements in animal models of AD however, the mechanism is still unclear. Studies have shown that the gut microbiota influences central nervous system disorders and that prebiotics can improve the cognition of hosts with AD, but these effects are not well understood. Thus, earlier intervention in AD is a top priority. Alzheimer's disease (AD), a progressive neurodegenerative disorder, lacks preclinical diagnostic biomarkers and therapeutic drugs.

Abacus chinese med louisville